What are the adverse reactions of crizotinib?

Crizotinib is a tyrosine kinase inhibitor (TKI) approved in 2011 for the treatment of locally advanced or metastatic non-small cell lung cancer with ALK mutations after clinical trials showed good objective response rates and increased progression-free survival. Crizotinib, also known as Xalkori, is an ATP-competitive inhibitor of ALK, ROS1 and MET tyrosine kinase receptors. The usual prescription is 250 mg twice daily.

Common side effects of crizotinib include nausea, diarrhea, vomiting, vision changes, fatigue, infection, loss of appetite, and several other side effects. Although mostly well tolerated, crizotinib can cause adverse side effects (Grade 3-5) leading to treatment discontinuation and decreased quality of life. In terms of symptom management, crizotinib performed well in relieving symptoms of pain, shortness of breath, cough, and insomnia. Crizotinib has fewer side effects and can maintain quality of life while improving progression-free survival and response rates. It is a first-line treatment drug superior to chemotherapy for the treatment of ALK-mutated non-small cell lung cancer.

The frequency and severity of these adverse reactions vary among individuals. Not all patients will experience these adverse reactions, and some may gradually lessen or disappear during treatment. However, if serious or persistent adverse reactions occur, the doctor should be informed promptly so that appropriate treatment can be carried out. Doctors usually provide detailed medication instructions and precautions when prescribing medication, and regularly monitor the patient's physical condition. During the treatment process, patients should follow the doctor's advice, take medication on time, and pay attention to adjustments in diet and living habits.